

INCARA PHARMACEUTICALS CORP

Form 8-K

January 15, 2003

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15 (d) of  
the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported) January 13, 2003

**INCARA PHARMACEUTICALS CORPORATION**

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or other jurisdiction of incorporation)

0-27410

(Commission File Number)

56-1924222

(I.R.S. Employer Identification Number)

P.O. Box 14287

79 T.W. Alexander Drive

4401 Research Commons, Suite 200

Research Triangle Park, NC 27709

(Address of principal executive office) (Zip Code)

Registrant's telephone number, including area code 919-558-8688

*This Report contains, in addition to historical information, statements by us with respect to expectations about our business and future results, which are forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements and other statements made elsewhere by us or our representatives, which are identified or qualified by words such as likely, will, suggests, expects, might, believe, should, may, estimates, potential, predict, continue, would, anticipates or plans, or similar expressions, are based on a number of factors, including those set forth herein, those set forth in our Annual Report on Form 10-K and in our other SEC filings, and including risks relating to uncertainties relating to the need to conserve cash and obtain funds for operations, the early stage of the products we are developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, our ability to obtain adequate patent protection and to enforce these rights and our ability to avoid infringement of the patent rights of others. All forward-looking statements are based on information available as of the date hereof, and we do not assume any obligation to update such forward-looking statements.*

**Item 5. Other Events and Regulation FD Disclosure**

On January 14, 2003, Incara Pharmaceuticals Corporation announced a cost reduction plan. On January 15, 2003 Incara announced that it and an affiliate of Elan Corporation, plc. terminated their agreement regarding the development and option to license Incara's catalytic antioxidant compounds for use in combination with radiation treatment of cancer. The press releases announcing these events are attached.

**Item 7. Financial Statements and Exhibits**

**(a) Exhibits**

- Exhibit 99.1 Press release issued January 14, 2003
- Exhibit 99.2 Press release issued January 15, 2003

